ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas A. Vassiliades, Jr
Lawrence H. Cohn
David H. Adams
Bruce W. Lytle
Michael J. Mack
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vassiliades, T. A.
Right arrow Articles by Williams, D. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vassiliades, T. A., Jr
Right arrow Articles by Williams, D. O.
Related Collections
Right arrow Cardiac - other

Ann Thorac Surg 2005;79:1812-1818
© 2005 The Society of Thoracic Surgeons

STS/AATS/SCAI position statement

The Clinical Development of Percutaneous Heart Valve Technology

A Position Statement of The Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI)

Thomas A. Vassiliades, Jr, MD, Peter C. Block, MD, Lawrence H. Cohn, MD, David H. Adams, MD, Jeffrey S. Borer, MD, Ted Feldman, MD, David R. Holmes, MD, Warren K. Laskey, MD, Bruce W. Lytle, MD, Michael J. Mack, MD, David O. Williams, MD

The first 300 words of the full text of this article appear below.


   Introduction
 

Dr Vassiliades is a consultant with Guidant. Dr Block is affiliated with Evalve, Corvalve. Dr Adams is a consultant with Edwards Lifesciences and 3F. Dr Lytle owns stock in Johnson and Johnson. Dr Mack is a consultant with Edwards Lifesciences and Medtronic. Drs Cohn, Borer, Feldman, Holmes, Laskey, and Williams report no conflicts of interest.

 


   Preamble
 
This joint position statement represents the combined efforts of four professional societies (Society of Thoracic Surgeons [STS], American Association for Thoracic Surgery [AATS], American College of Cardiology [ACC], and Society for Cardiovascular Angiography and Interventions [SCAI]), two government agencies (the U.S. Food and Drug Administration [FDA] and the Centers for Medicare and Medicaid Services [CMS]), and numerous industry representatives to assess the foreseeable directions of a class of emerging technologies being developed to enable the percutaneous treatment of cardiac valve dysfunction. Percutaneous heart valve technology (PHVT) is a less invasive means of treating valvular heart disease. The goals of the interdisciplinary group have been to establish cooperation, identify consensus and controversy, and formulate clinical guidelines for the continued development of PHVT.


   Process
 
On April 22, 2004, the STS/AATS Committee/Workforce for the Assessment of New Technology (Appendix 1) organized a workshop on PHVT. Included were representatives from the STS, the AATS, the ACC, and SCAI. Also in attendance were representatives from the FDA's Division of Cardiovascular Devices, Circulatory Support and Prosthetic Devices Branch, CMS, and industry representatives (Appendix 2). Clinical aspects of PHVT were initially addressed in small groups with representatives from each of the constituencies followed by a summary report and discussion amongst the entire group. All participants of the workshop and writing group members completed a disclosure questionnaire documenting all outside relationships that might be perceived as real or potential conflicts of interest [1]. Current crucial issues addressed were: 1) trial design, 2) . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
F. De Robertis, A. Asgar, S. Davies, N. Delahunty, A. Kelleher, R. Trimlett, M. Mullen, and N. Moat
The left axillary artery -- a new approach for transcatheter aortic valve implantation
Eur J Cardiothorac Surg, November 1, 2009; 36(5): 807 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. J. Antunes
Percutaneous aortic valve implantation. The demise of classical aortic valve replacement?
Eur. Heart J., June 1, 2008; 29(11): 1339 - 1341.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Vahanian, O. Alfieri, N. Al-Attar, M. Antunes, J. Bax, B. Cormier, A. Cribier, P. De Jaegere, G. Fournial, A. P. Kappetein, et al.
Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Eur. Heart J., June 1, 2008; 29(11): 1463 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Cardiothorac SurgHome page
M. J. Antunes
Off-pump aortic valve replacement with catheter-mounted valved stents. Is the future already here?
Eur J Cardiothorac Surg, January 1, 2007; 31(1): 1 - 3.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Morreim, M. J. Mack, and R. M. Sade
Surgical Innovation: Too Risky to Remain Unregulated?
Ann. Thorac. Surg., December 1, 2006; 82(6): 1957 - 1965.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. M. Gillinov and D. M. Cosgrove III
Reply
Ann. Thorac. Surg., June 1, 2006; 81(6): 2339 - 2340.
[Full Text] [PDF]

Home page
 CirculationHome page
R. J. Shemin
Percutaneous Valve Intervention: A Surgeon's Perspective
Circulation, February 14, 2006; 113(6): 774 - 775.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.